Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

@article{Annunziata2010VandetanibDT,
  title={Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.},
  author={Christina M Annunziata and Amanda J. Walker and L. L. Minasian and Minshu Yu and Herbert L Kotz and Bradford J. Wood and Katherine R Calvo and Peter M Choyke and Daniel Kimm and Seth Steinberg and Elise C. Kohn},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 2},
  pages={664-72}
}
PURPOSE To evaluate clinical activity and target modulation of vandetanib in women with recurrent ovarian cancer. EXPERIMENTAL DESIGN A phase II trial of orally administered vandetanib 300 mg daily was designed to include analyses of target inhibition through paired biopsies and dynamic imaging. Core 18-gauge needle biopsies and dynamic contrast-enhanced magnetic resonance imaging were obtained before initiation of therapy and 6 weeks into therapy. Biopsy samples were subjected to reverse… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

New guidelines to evalClin Cancer Res

  • P Therasse, SG Arbuck, EA Eisenhauer
  • J Natl Cancer Inst 2000;92:205–16
  • 2010
2 Excerpts

Epithelian ovarian cancer

  • GF Fleming, BM Ronnett, J Seidman, RJ Zaino, SC. Rubin
  • 2009
1 Excerpt

Tumor invasion, angiogenesis and metastasis: biology and clinical application

  • CM Annunziata, NS Azad, ER Hoskins, EC. Kohn
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…